Skip to main content
Fig. 3 | Molecular Brain

Fig. 3

From: Reduced expression of somatostatin in GABAergic interneurons derived from induced pluripotent stem cells of patients with parkin mutations

Fig. 3

Changes in the expression of SST in PARK2-derived GABAergic neurons. (a) Quantitative gene-expression analysis of SST in control and PARK2 (PA and PB) iPSC-derived GABAergic neurons (day 60). Control is presented as one column combining and averaging two cell lines (WD39 and 201B7). Data are shown as means ± SEM. Statistical analysis was performed using one-way ANOVA with Bonferroni’s post-hoc test (n = 5), **p < 0.01, ***p < 0.001 compared to control. (b) Quantitative gene-expression analysis of GAD1/67 in control and PARK2 (PA and PB) iPSC-derived GABAergic neurons (day 60). Control is presented as one column combining and averaging two cell lines (WD39 and 201B7). Data are shown as means ± SEM. Statistical analysis was performed using one-way ANOVA with Bonferroni’s post-hoc test (n = 5). (c) Immunocytochemical analysis for GABA and SST of control and PARK2 (PA and PB) iPSC-derived GABAergic neurons (day 60). Scale bar, 50 μm. (d) Quantification of the percentages of SST- and GABA-positive cells derived from control and PARK2 (PA and PB) iPSCs. Data are presented as means ± SEM. Statistical analysis was performed using one-way ANOVA with Bonferroni’s post-hoc test (n = 3), ***p < 0.001 compared to control. (e) Quantification of fluorescence intensity for SST levels. Data are presented as means ± SEM. Statistical analysis was performed using one-way ANOVA with Bonferroni’s post-hoc test (n = 3), *p < 0.05, ***p < 0.001 compared to control

Back to article page